Login / Signup

Correlation between BAP1 Localization, Driver Mutations, and Patient Survival in Uveal Melanoma.

Yasemin C ColeYu Zhi ZhangBeatrice GalloAdam P JanuszewskiAnca NastaseDavid J EssexCaroline M H ThaungVictoria M L CohenMandeep S SagooAnne M Bowcock
Published in: Cancers (2022)
Uveal melanoma (UM) is an uncommon but highly aggressive ocular malignancy. Poor overall survival is associated with deleterious BAP1 alterations, which frequently occur with monosomy 3 (LOH3) and a characteristic gene expression profile. Tumor DNA from a cohort of 100 UM patients from Moorfields Biobank (UK) that had undergone enucleation were sequenced for known UM driver genes ( BAP1 , SF3B1 , EIF1AX , GNAQ , and GNA11 ). Immunohistochemical staining of BAP1 and interphase FISH for chromosomes 3 and 8 was performed, and cellular localization of BAP1 was correlated with BAP1 mutations. Wildtype (WT) BAP1 staining was characterized by nBAP1 expression with <10% cytoplasmic BAP1 (cBAP1). Tumors exhibited heterogeneity with respect to BAP1 staining with different percentages of nBAP1 loss: ≥25% loss of nuclear BAP1 (nBAP1) was superior to chr8q and LOH3 as a prognostic indicator. Of the successfully sequenced UMs, 38% harbored oncogenic mutations in GNA11 and 48% harbored mutations in GNAQ at residues 209 or 183. Of the secondary drivers, 39% of mutations were in BAP1 , 11% were in EIF1AX , and 20% were in the SF3B1 R625 hotspot. Most tumors with SF3B1 or EIF1AX mutations retained nuclear BAP1 (nBAP1). The majority of tumor samples with likely pathogenic BAP1 mutations, regardless of mutation class, displayed ≥25% loss of nBAP1. This included all tumors with truncating mutations and 80% of tumors with missense mutations. In addition, 60% of tumors with truncating mutations and 82% of tumors with missense mutations expressed >10% cBAP1.
Keyphrases
  • end stage renal disease
  • genome wide
  • autism spectrum disorder
  • chronic kidney disease
  • binding protein
  • patient reported outcomes
  • patient reported